A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2019
Price : $35 *
At a glance
- Drugs Peficitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 09 Feb 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.